Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Combinations in HER2+ and HER2- Breast Cancer
NCT02605915Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2015
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in HER2-positive breast cancer and breast cancer (10 cohorts), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities and Percentage of Participants With Adverse Events. Started Dec 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
HER2-positive breast cancerbreast cancer
Beyond the preview
Go deeper on NCT02605915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605915.